Whatâs new in Asthma Treatment? – MM1703
Large studies in patients with asthma have revealed different patterns of airway inflammation (asthma phenotypes) that
suggest the possibility of an individualised approach to asthma management. Doctors and patients now have a
wider choice of inhaled corticosteroid (ICS) plus longacting beta agonist (LABA) combinations and inhaler
devices. Evidence suggests that addition of the long-acting muscarinic antagonist tiotropium to ICS plus LABA therapy
may reduce asthma exacerbations while providing modest bronchodilatation. The monoclonal antibodies omalizumab
were recently introduced for the management of patients with severe allergic asthma and severe eosinophilic asthma, respectively.
Modern Medicine – March 2017
